Your browser doesn't support javascript.
loading
New DiaP277 analogue shifts DCs to tolerogenic, and modulates NF-Kß1 to suppress autoreactive T lymphocytes in the type 1 diabetic mice.
Alahdal, Murad; Liangliang, Jing; Shiping, Lu; Yun, Xing; Gao, Huashan; Jialei, Zhou; Hassan, Waseem; Jin, Liang; Rongyue, Cao.
Afiliación
  • Alahdal M; a State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, School of life Science and Technology , China Pharmaceutical University , Nanjing , PR China.
  • Liangliang J; b Medical Laboratory Department, Faculty of Medicine and Health Sciences , Hodeidah University , Al Hudaydah , Yemen.
  • Shiping L; c Minigene Pharmacy Laboratory, School of Life Science & Technology , China Pharmaceutical University , Nanjing , PR China.
  • Yun X; a State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, School of life Science and Technology , China Pharmaceutical University , Nanjing , PR China.
  • Gao H; a State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, School of life Science and Technology , China Pharmaceutical University , Nanjing , PR China.
  • Jialei Z; a State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, School of life Science and Technology , China Pharmaceutical University , Nanjing , PR China.
  • Hassan W; c Minigene Pharmacy Laboratory, School of Life Science & Technology , China Pharmaceutical University , Nanjing , PR China.
  • Jin L; c Minigene Pharmacy Laboratory, School of Life Science & Technology , China Pharmaceutical University , Nanjing , PR China.
  • Rongyue C; d Department of Pharmacy , COMSATS University Islamabad , Lahore Campus.
Autoimmunity ; 51(5): 210-220, 2018 08.
Article en En | MEDLINE | ID: mdl-30382756
Therapeutic efficacy of P277 against type 1 diabetes was extensively investigated and clinically evidenced. Clinical trials Phases I and II concluded promising results, while the data of P277 immunogenicity in Phase III trials represented weak responses that led to abolish medical use. But, a therapeutic performance of P277 cannot be forgotten. So, in order to exploit its therapeutic benefits and improve its immunogenicity, we developed a new analogue VP to optimize therapeutic efficacy and enhancing immunosuppressive modulations. However, new analogue was purified, and then used to immunize diabetic NOD mice to investigate antidiabetic effects through modulation of immunological status. So, DCs immune responses, relative TLRs, MyD88, and NF-Kß1 mRNA expression on DCs and splenocytes under VP effect were tested. Circulating and intracellular cytokines were also evaluated at treated and non-treated mice. Splenic T lymphocytes proliferation (Th1 and Treg cells) were also determined. Results revealed that VP significantly down regulates DCs maturation through TLR2, TLR4, and MyD88 pathways. It also shifts DCs to a tolerogenic polarization through NF-Kß1 pathway that mediates Th1 immunosuppression and enhances iTreg expanding in type1diabetes mice. Meanwhile, we noticed that VP significantly enhances iTreg CD25 + FoxP3+ proliferation. In conclusion, VP showed promising immune potential to modulate immune regulatory responses and shifts DCs to suppress autoreactive Th1 cells which ameliorated immunosuppressive potency in the type1 diabetic mice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Autoinmunidad / Chaperonina 60 / Diabetes Mellitus Tipo 1 / Tolerancia Inmunológica / Inmunosupresores Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Autoimmunity Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Autoinmunidad / Chaperonina 60 / Diabetes Mellitus Tipo 1 / Tolerancia Inmunológica / Inmunosupresores Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Autoimmunity Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido